Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 – PRODIGE 107 – FFCD 2306 – COLOSOTO trial
Digestive and Liver Disease · 2026-07 · 58 (7) · 966-972
DOI: 10.1016/j.dld.2026.04.009 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Digestive and Liver Disease, 2026-07. Verfasst von Adrien Grancher und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepato-Gastroenterology and Digestive Oncology, Rouen University Hospital, INSERM ANTICIPE U1086, Rouen, France. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Fluorouracil, Panitumumab, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Amgen, The Amgen Foundation Inc.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepato-Gastroenterology and Digestive Oncology, Rouen University Hospital, INSERM ANTICIPE U1086, Rouen, France.
- Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Hematology, Oncology and Cancer Immunology, Berlin, Germany.
- Department of Medical Oncology, Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca (IBSAL), Salamanca, Spain.
- Fédération Francophone de Cancérologie Digestive (FFCD), EPICAD INSERM LNC-UMR 1231, Faculté de Médecine, University of Burgundy and Franche Comté, Dijon, France.
- Institut Mutualiste Montsouris, Service oncologie, Paris, France.
Förderung
- Amgen
- The Amgen Foundation Inc
Zitieren
APA
Grancher, A., Landi, M., Ballhausen, A., Vidal Tocino, R., Alig, A., Taravella, A., Le Malicot, K., Soularue, E., Gallois, C., Guarssifi, M., Pelkowski, M., Beltran, M., Kochen, L., Delliponti, L., Taïeb, J., Sastre, J., Modest, D. P., Cremolini, C., Mazard, T., & Tougeron, D. (2026). Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 – PRODIGE 107 – FFCD 2306 – COLOSOTO trial. Digestive and Liver Disease, 58(7), 966-972. https://doi.org/10.1016/j.dld.2026.04.009
Vancouver
Grancher A, Landi M, Ballhausen A, Vidal Tocino R, Alig A, Taravella A, et al. Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 – PRODIGE 107 – FFCD 2306 – COLOSOTO trial. Digestive and Liver Disease. 2026;58(7):966-972. doi:10.1016/j.dld.2026.04.009
BibTeX
@article{Grancher2026,
author = {Grancher, Adrien and Landi, Matteo and Ballhausen, Alexej and Vidal Tocino, Rosario and Alig, Annabel and Taravella, Ada and Le Malicot, Karine and Soularue, Emilie and Gallois, Claire and Guarssifi, Meriem and Pelkowski, Manon and Beltran, Marta and Kochen, Lisa and Delliponti, Laura and Taïeb, Julien and Sastre, Javier and Modest, Dominik Paul and Cremolini, Chiara and Mazard, Thibault and Tougeron, David},
title = {Sotorasib plus panitumumab and 5-fluorouracil in first-line treatment of patients with unresectable KRAS G12C mutated colorectal cancer unfit for a doublet/triplet chemotherapy: ENGIC 01 – PRODIGE 107 – FFCD 2306 – COLOSOTO trial},
journal = {Digestive and Liver Disease},
year = {2026},
volume = {58},
number = {7},
pages = {966--972},
doi = {10.1016/j.dld.2026.04.009}
}
EUVIMED